NCT05448391View on ClinicalTrials.gov

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 13, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

December 30, 2024

Conditions
Familial Mediterranean Fever
Interventions
DRUG

RIST4721

RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets

Sponsors
All Listed Sponsors
lead

Aristea Therapeutics, Inc.

INDUSTRY

NCT05448391 - A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF) | Biotech Hunter | Biotech Hunter